ERA 223 Study | Concerns About Using Radium-223 and Abiraterone

by | Dec 2017

The IDMC’s Recommendation to Unblind a Phase III Trial of Radium-223 in Combination with Abiraterone Acetate for Prostate Cancer



Breaking News about the ERA 223 Trial, a phase III trial of radium-223 in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded:
In early December 2017, the ERA 223 trial released safety concerns of the combination arm of abiraterone acetate and radium-223 of prostate cancer patients. The information released suggests that patients receiving radium-223 with abiraterone acetate had more incidences of bone fractures and deaths.